96 related articles for article (PubMed ID: 10694841)
21. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Vollmer TL; Wynn DR; Alam MS; Valdes J
Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
[TBL] [Abstract][Full Text] [Related]
22. Circulating CD8+CD56-perforin+ T cells are increased in multiple sclerosis patients.
Giovanni F; Domenico P; Alessandro M; Raffaele I; Viviana N; Katia PA; Paola BA
J Neuroimmunol; 2011 Dec; 240-241():137-41. PubMed ID: 22001684
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal analysis of physical activity and symptoms as predictors of change in functional limitations and disability in multiple sclerosis.
Motl RW; McAuley E
Rehabil Psychol; 2009 May; 54(2):204-10. PubMed ID: 19469611
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
25. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients.
Petereit HF; Nolden S; Schoppe S; Bamborschke S; Pukrop R; Heiss WD
Mult Scler; 2002 Dec; 8(6):492-4. PubMed ID: 12474989
[TBL] [Abstract][Full Text] [Related]
26. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
27. Defective Fas ligand production in lymphocytes from MS patients.
Macchi B; Matteucci C; Nocentini U; Tacconi S; Pagnini V; Mastino A; Caltagirone C
Neuroreport; 2001 Dec; 12(18):4113-6. PubMed ID: 11742248
[TBL] [Abstract][Full Text] [Related]
28. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.
Giovannoni G
Mult Scler; 2011 Mar; 17(3):259-61. PubMed ID: 21362756
[No Abstract] [Full Text] [Related]
30. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
[TBL] [Abstract][Full Text] [Related]
31. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
32. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years.
Lopatinskaya L; Zwemmer J; Uitdehaag B; Lucas K; Polman C; Nagelkerken L
Mult Scler; 2006 Dec; 12(6):704-9. PubMed ID: 17262997
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis.
Wilczak N; Ramsaransing GS; Mostert J; Chesik D; De Keyser J
Mult Scler; 2005 Feb; 11(1):13-5. PubMed ID: 15732261
[TBL] [Abstract][Full Text] [Related]
34. Altered cytokine responses to cognitive stress in multiple sclerosis patients with fatigue.
Heesen C; Koehler G; Gross R; Tessmer W; Schulz KH; Gold SM
Mult Scler; 2005 Feb; 11(1):51-7. PubMed ID: 15732267
[TBL] [Abstract][Full Text] [Related]
35. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
Skrzipek S; Vogelgesang A; Bröker BM; Dressel A
Mult Scler; 2012 May; 18(5):674-8. PubMed ID: 22025329
[TBL] [Abstract][Full Text] [Related]
37. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
38. Immunological differences between classical phenothypes of multiple sclerosis.
Iwanowski P; Losy J
J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
[TBL] [Abstract][Full Text] [Related]
39. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
40. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
